The palmitoylation of metastasis suppressor KAI1/CD82 is important for its motility- and invasiveness-inhibitory activity

Cancer Research

Volumn 64, Issue 20, 2004, Pages 7455-7463

  Zhou, Bin ^a   Liu, Li ^a   Reddivari, Muralidhar ^a   Zhang, Xin A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CD82 ANTIGEN; CYSTEINE; PROTEIN; PROTEIN P130; TETRASPANIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INVASION; CELL MEMBRANE; CELL MIGRATION; CELL MOTILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; CYTOSKELETON; HUMAN; HUMAN CELL; INHIBITION KINETICS; METASTASIS; MUTANT; PALMITOYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CELL MOVEMENT; CRK-ASSOCIATED SUBSTRATE PROTEIN; HUMANS; KANGAI-1 PROTEIN; MALE; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASM METASTASIS; PALMITATES; PROSTATIC NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CRK; RATS; RETINOBLASTOMA-LIKE PROTEIN P130; SUBCELLULAR FRACTIONS; TRANSFECTION;

EID: 5644243063     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1574     Document Type: Article

References (62)

1. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome IIp11.2. Science (Wash. DC) 1995;268:884-6.
2. Liu FS, Chen JT, Dong JT, et al. KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma. Am J Pathol 2001;159:1629-34.
3. Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, Barrett JC. Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 1999;59:5724-31.
4. Takaoka A, Hinoda Y, Sato S, et al. Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells. Jpn J Cancer Res 1998;89:397-404.
5. Yang X, Wei LL, Tang C, Slack R, Mueller S, Lippman ME. Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res 2001;61:5284-8.
6. Dong JT, Suzuki H, Pin SS, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996;56:4387-90.
7. Ueda T, Ichikawa T, Tamaru J, et al. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol 1996;149:1435-40.
8. Uchida S, Shimada Y, Watanabe G, et al. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in esophageal squamous cell carcinoma. Br J Cancer 1999;79:1168-73.
9. Yu Y, Yang JL, Markovic B, et al. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin Cancer Res 1997;3:1045-9.
10. Yang X, Wei L, Tang C, Slack R, Montgomery E, Lippman M. KAI1 protein is down-regulated during the progression of human breast cancer. Clin Cancer Res 2000;6:3424-9.
11. Higashiyama M, Kodama K, Yokouchi H, et al. KAI1/CD82 expression in non-small cell lung carcinoma is a novel, favorable prognostic factor: an immunohistochemical analysis. Cancer (Phila.) 1998;83:466-74.
12. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996;56:1751-5.
13. Huang CI, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 1998;153:973-83.
14. Ono M, Handa K, Withers DA, Hakomori S. Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Cancer Res 1999;59:2335-9.
15. Schoenfeld N, Bauer MK, Grimm S. The metastasis suppressor gene C33/CD82/ KAI1 induces apoptosis through reactive oxygen intermediates. FASEB J 2004;18:158-60.
16. Odintsova E, Sugiura T, Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Cur Biol 2000;10:1009-12.
17. Odintsova E, Voortman J, Gilbert E, Berditchevski P. Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. J Cell Sci 2003; 116:4557-66.
18. Boucheix C, Rubinstein E. Tetrsapanins. Cell Mol Life Sci 2001;58:1189-205.
19. 1 integrin with the tetraspanin-enriched microdomains and affects integrin-dependent signaling. J Biol Chem 2002; 277:36991-7000.
20. Tarrant JM, Robb L, van Spriel AB, Wright MD. Tetraspanins, molecular organizers of the leukocyte surface. Trend Immunol 2003;24:610-7.
21. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 2003;19:397-422.
22. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 1997;11:428-42.
23. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001;114:4143-51.
24. 3 integrin in microdomain is promoted by GM3 ganglioside, leading to inhibition of laminin-5-dependent cell motility. J Biol Chem 2002;277:34349-58.
25. Charrin S, Manie S, Thiele C, et al. A physical and functional link between cholesterol and tetraspanins. Eur J Immunol 2003;33:2479-89.
26. Resh MD. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim Biophys Acta 1999;1451:1-16.
27. Linder ME, Deschenes RJ. New insights into the mechanisms of protein palmitoylation. Biochemistry 2003;42:4311-20.
28. Dunphy JT, Linder ME. Signalling functions of protein palmitoylation. Biochim Biophys Acta 1998;1436:245-61.
29. Bijlmakers MJ, Marsh M. The on-off story of protein palmitoylation. Trends Cell Biol 2003;13:32-42.
30. Seehafer JG, Tang SC, Slupsky JR, Shaw AR. The functional glycoprotein CD9 is variably acylated: localization of the variably acylated region to a membrane-associated peptide containing the binding site for the agonistic monoclonal antibody 50H. 19. Biochim Biophys Acta 1988;957:399-410.
31. Seehafer JG, Slupsky JR, Tang SC, Masellis-Smith A, Shaw AR. Myristic acid is incorporated into the two acylatable domains of the functional glycoprotein CD9 in ester, but not in amide bonds. Biochim Biophys Acta 1990;1039:218-26.
32. Levy S, Nguyen VQ, Andria ML, Takahashi S. Structure and membrane topology of TAPA-1. J Biol Chem 1991;266:14597-602.
33. Charrin S, Manié S, Qualid M, Billard M, Boucheix C, Rubinstein E. Differential stability of tetraspanin/tetraspanin interactions: role of palmitoylation. FEBS Lett 2002;516:139-44.
34. Yang X, Claas C, Kraeft SK, et al. Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology. Mol Biol Cell 2002;13:767-81.
35. Fukudome K, Furuse M, Imai T, et al. Identification of membrane antigen C33 recognized monoclonal antibodies inhibitory to HTLV-1 induced syncytium formation: altered glycosylation of C33 antigen in HTLV-1-positive cells. J Virol 1992; 66:1394-401.
36. Nojima Y, Hirose T, Tachibana K, et al. The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T-cell activation and adhesion. Cell Immunol 1993;152:249-60.
37. Zhang XA, Hemler ME. Interaction of the integrin beta1 cytoplasmic domain with ICAP-1 protein. J Biol Chem 1999;274:11-9.
38. CAS-Crk coupling in KAI1/ CD82-mediated suppression of cell migration. J Biol Chem 2003;278:27319-28.
39. 3 QPSXXE motif regulates signaling, motility, and cytoskeletal engagement. Mol Biol Cell 2001;12:351-65.
40. 1 integrins. J Biol Chem 2001;276:25005-13.
41. Zhang XA, Lane WS, Charrin S, Rubinstein E, Liu L. EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells. Cancer Res 2003;63:2665-74.
42. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
43. Kaighn ME, Narayan S, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostate carcinoma cell line (PC3). Investig Urol 1978;17:16-23.
44. Clark KL, Oelke A, Johnson ME, Eilert KD, Simpson PC, Todd SC. CD81 associates with 14-3-3 in a redox-regulated palmitoylation-dependent manner. J Biol Chem 2004;279:19401-6.
45. 1 integrin complex during cellular morphogenesis. Mol Biol Cell 2002;13:1-11.
46. Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol 1998;140:961-72.
47. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science (Wash. DC) 2003;302:1704-9.
48. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol 2004;265:23-32.
49. Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003;112:453-65.
50. Claas C, Stipp CS, Hemler ME. Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem 2001;276:7974-84.
51. Boesze-Battaglia K, Dispoto J, Kahoe MA. Association of a photoreceptor-specific tetraspanin protein, ROM-1, with Triton X-100-resistant membrane rafts from rod outer segment disk membranes. J Biol Chem 2002;277:41843-9.
52. Cherukuri A, Shoham T, Sohn HW, et al. The tetraspanin CD81 is necessary for partitioning of coligated CD19/CD21-B cell antigen receptor complexes into signaling-active lipid rafts. J Immunol 2004;172:370-80.
53. Blanpain C, Wittamer V, Vanderwinden JM, et al. Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways. J Biol Chem 2001;276:23795-804.
54. Percherancier Y, Planchenault T, Valenzuela-Fernandez A, Virelizier JL, Arenzana-Seisdedos F, Bachelerie F. Palmitoylation-dependent control of degradation, life span, and membrane expression of the CCR5 receptor. J Biol Chem 2001;276:31936-44.
55. Tanaka K, Nagayama Y, Nishihara E, Namba H, Yamashita S, Niwa M. Palmitoylation of human thyrotropin receptor: slower intracellular trafficking of the palmitoylation-defective mutant. Endocrinology 1998;139:803-6.
56. Schulein R, Liebenhoff U, Muller H, Birnbaumer M, Rosenthal W. Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site. Biochem J 1996;313:611-6.
57. Sadeghi HM, Innamorati G, Dagarag M, Birnbaumer M. Palmitoylation of the V2 vasopressin receptor. Mol Pharmacol 1997;52:21-9.
58. Gao Z, Ni Y, Szabo G, Linden J. Palmitoylation of the recombinant human A1 adenosine receptor: enhanced proteolysis of palmitoylation-deficient mutant receptors. Biochem J 1999;342:387-95.
59. Camp LA, Verkruyse LA, Afendis SJ, Slaughter CA, Hofmann SL. Molecular cloning and expression of palmitoyl-protein thioesterase. J Biol Chem 1994;269:23212-9.
60. Bretscher MS, Aguado-Velasco C. Membrane traffic during cell locomotion. Curr Opin Cell Biol 1998;10:537-41.
61. Cavalli V, Corti M, Gruenberg J. Endocytosis and signaling cascades: a close encounter. FEBS Lett 2001;498:190-6.
62. Di Fiore PP, Gill GN. Endocytosis and mitogenic signaling. Curr Opin Cell Biol 1999;11:483-8.